Abbott Cardiovascular is at the forefront of structural heart therapies, dedicated to transforming patient care through innovative solutions. With a comprehensive portfolio, Abbott offers advanced products for the treatment of a range of conditions, including valvular heart disease, congenital heart defects, and stroke risk reduction. Their standout offerings include the MitraClip for mitral regurgitation, the Portico TAVI system for aortic stenosis, and the Amplatzer family of occluders for left atrial appendage and patent foramen ovale closures.

Driven by a patient-first approach, Abbott emphasizes the importance of clinical evidence, continuously engaging in robust clinical trials to ensure effective treatment options. They also prioritize physician support through extensive training and resources, enabling healthcare teams to deliver the best outcomes. As a leader in the cardiovascular field, Abbott Cardiovascular is committed to enhancing both the quality of life for patients and the experience of healthcare providers, setting a new standard in the treatment of structural heart diseases